Dihexa: Evidence, Safety, Dosing, and Access Questions

Dihexa is an angiotensin IV analogue studied mainly in preclinical models as a proposed HGF/c-Met pathway modulator. The evidence is limited: Chia’s evidence grade is C, meaning human research exists but no randomized trials are indexed. Chia does not offer Dihexa; this page is education-only.

What it is

Dihexa is commonly described as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, a peptide-like angiotensin IV analogue. Angiotensin IV-derived peptides have been studied for procognitive and synaptogenic effects through the hepatocyte growth factor, or HGF, and c-Met receptor system 1.

Names and classification

The names you may see include Dihexa, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, angiotensin IV analogue, angiotensin IV-derived peptide, and HGF mimetic. These terms do not mean the same thing in every paper, but they point to the same research family: compounds designed around angiotensin IV biology and HGF/c-Met signaling 1.

What researchers have studied it for

Researchers have mainly studied Dihexa-related compounds in experimental cognition, neurodegeneration, ototoxicity, and cell-differentiation models. A systematic review of angiotensin IV and angiotensin-(1-7) described cognitive effects across experimental studies, not randomized patient trials 2.

For a deeper companion read, our earlier Dihexa cognitive enhancement peptide guide explains why early mechanism studies can be interesting but still not enough to prove patient benefit.

Mechanism of action

Dihexa’s mechanism in humans is unestablished. The proposed mechanism is based on experimental work linking angiotensin IV-derived peptides to HGF/c-Met activation, synaptogenesis, and downstream signaling pathways such as PI3K/AKT 1, 3.

Angiotensin IV analogues and the HGF/c-Met system

HGF means hepatocyte growth factor, a signaling protein involved in growth, repair, and cell communication. c-Met is the receptor HGF acts on. Reviews from Wright, Harding, Benoist, and colleagues describe the brain HGF/c-Met system as a research target in Alzheimer’s disease models, but that is not the same as proving a treatment effect in people 1, 4.

Synaptogenic and procognitive mechanisms studied in experimental models

Synaptogenesis means the formation of connections between nerve cells. Benoist and colleagues reported that procognitive and synaptogenic effects of angiotensin IV-derived peptides depended on HGF/c-Met activation in experimental systems 1.

In an APP/PS1 animal model used in Alzheimer’s disease research, Sun and colleagues reported that Dihexa rescued cognitive impairment and memory deficits through a pathway involving PI3K/AKT signaling 3. This was animal evidence, so it cannot show that Dihexa improves cognition or changes dementia outcomes in humans.

Why preclinical mechanisms do not prove clinical benefit

A mechanism can be real in a cell or animal model and still fail in people. Human cognition, dementia, and neuropsychiatric symptoms involve many brain systems, drug-exposure questions, safety questions, and disease differences that experimental models cannot fully answer 2, 4.

Evidence

Dihexa has an assigned evidence grade of C — human research exists, none of it randomised. The key patient takeaway is simple: the research is early and is not enough to prove cognitive benefit in people.

What animal and cell studies suggest

Animal studies are the main source of cognition-related Dihexa claims. McCoy and colleagues evaluated metabolically stabilized angiotensin IV analogues as possible procognitive or antidementia agents in preclinical work 5. Sun and colleagues studied Dihexa in an APP/PS1 mouse model and reported memory-related effects tied to PI3K/AKT signaling 3.

Other preclinical work broadens the research map but does not prove a human treatment effect. Uribe and colleagues reported that an HGF mimetic protected lateral line hair cells from aminoglycoside exposure in a non-human ototoxicity model 6. Wells and colleagues studied an angiotensin IV analogue in rats with 3-nitropropionic-acid-induced Huntington’s disease-like symptoms 7.

Cell studies also appear in the literature. Pan and colleagues used a small-molecule strategy involving human pluripotent stem cells to generate hepatic cells, and Mathapati and colleagues described small-molecule-directed hepatocyte-like cell differentiation 8, 9. These are laboratory findings, not evidence that Dihexa changes symptoms in people.

What human evidence can and cannot support

The supplied PubMed record count says human research exists, but the listed records do not include randomized human Dihexa trials. Because of that, the evidence cannot support claims that Dihexa improves cognition, reverses cognitive decline, treats dementia, or extends lifespan in humans 2, 4.

Why there are no randomized human trials to rely on

Randomized trials matter because they compare a treatment with placebo or another control in people. The supplied records include experimental reviews, animal work, and cell research, but no randomized Dihexa patient trial that can define benefits, adverse-effect rates, dosing, or interactions 2, 4.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.

Reported dosing ranges

Dihexa has no established patient dosing standard in the supplied published evidence. No human dosing has been published in the supplied records.

Why there is no established patient dosing standard

A patient dosing standard usually comes from human trials, labeling, or clinical guidelines. The supplied Dihexa records include animal, cell, and review literature, but no randomized human trial or label-based dosing source 2, 4.

What online dosing ranges cannot tell you

Online dosing ranges cannot tell you whether a product is what the label says, whether it is sterile, whether impurities are present, or whether the risk makes sense for your health history. That is especially important when the published Dihexa evidence does not include randomized patient dosing studies 2, 4.

Why dosing decisions require clinician review

Dosing decisions for any experimental peptide question should start with a licensed clinician who can review diagnoses, medications, pregnancy status, neurologic history, cancer history, psychiatric history, and goals. This article should not be used as a dosing protocol.

Legal status

Our regulatory log holds no confirmed federal action for Dihexa. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.

Safety

Dihexa safety in people is not well defined by the supplied evidence. The listed records do not include randomized human trials that could estimate common side effects, serious adverse events, longer-term risks, or risk by dose 2, 4.

Limited human safety data

The absence of randomized safety data is not reassurance. It means uncertainty. Experimental reports can describe mechanisms and model findings, but they do not give the same safety information as controlled clinical trials in patients 2, 4.

Concerns with unverified products

Research-chemical products may carry identity, impurity, sterility, purity, and labeling risks. “Research use only” material is not made for people, and a label does not prove that a vial or powder contains the stated compound or concentration.

When to seek medical advice before considering any experimental peptide

Seek medical advice before considering any experimental peptide if you have cognitive symptoms, seizures, movement symptoms, cancer history, psychiatric symptoms, liver or kidney disease, pregnancy, breastfeeding, or multiple medications. Dihexa-related research touches brain and growth-factor pathways, so risk review matters 1, 4.

Interactions

Dihexa interaction studies in people have not been published in the supplied records. That means drug, supplement, disease, and pregnancy interaction risk is unknown from this evidence base, not that there is no risk 2, 4.

Why interaction data are limited

Interaction data usually come from human pharmacology studies, clinical trials, labels, or post-marketing surveillance. The supplied Dihexa evidence does not include those kinds of patient data, so it cannot define interactions with psychiatric medicines, neurologic medicines, blood-pressure medicines, cancer therapies, supplements, or alcohol 2, 4.

Medication, neurologic, cancer, pregnancy, and psychiatric-history considerations

Because Dihexa is discussed around HGF/c-Met and brain signaling, a clinician should know about cancer history, neurologic disease, psychiatric history, pregnancy plans, and all prescription or nonprescription substances before any peptide-related decision is made 1, 4.

How to obtain it legally

Dihexa is not offered by Chia. We include it because patients ask about it, and an honest reference page should make clear when the evidence is thin and when we do not provide the compound.

Start with a licensed clinician rather than a research-chemical vendor

A safer process starts with a licensed clinician, not a research-chemical vendor. A clinician can review symptoms, goals, medical history, medications, risk factors, and whether any evaluation is needed before a peptide question is considered.

What a legitimate clinical process usually includes

A legitimate clinical process usually includes a medical history, eligibility review, risk discussion, and pharmacy verification when a prescription is clinically appropriate. A prescription requires a medical evaluation and is not guaranteed. At Chia, medications we do offer are reviewed by licensed US providers, compounded by state-licensed US 503A pharmacies, and shipped to the patient’s door; compounded drugs are not FDA-approved.

Why Chia does not offer Dihexa

Chia does not offer Dihexa because our current catalog is limited to treatments we can support through our clinical and pharmacy process. For cognitive or longevity questions, we may write about research compounds we do not offer, such as Dihexa, alongside better-known topics like Semax, Selank, rapamycin, and metformin.

How does Dihexa compare with better-known cognitive or longevity compounds?

Dihexa is usually discussed as a cognition-focused research peptide analogue, while Semax and Selank are often discussed in nootropic or anxiety-related peptide conversations, and rapamycin or metformin are discussed in longevity research. These are different categories, and none should be treated as interchangeable.

FAQ

Keep reading

Peptides

Semax: Evidence, Safety, Dosing and Legal Status

Longevity

Best Peptides for Energy: What the Research Actually Shows

Peptides

Semax: the ACTH-derived nootropic and neuroprotectant — 2026 evidence-based guide